# Treating Kidney Donors With Valganciclovir to Reduce Viral Transmission to Recipients

> **NCT01329185** · PHASE2 · COMPLETED · sponsor: **University of Minnesota** · enrollment: 17 (actual)

## Conditions studied

- EBV Viremia
- CMV Viremia

## Interventions

- **DRUG:** Valganciclovir
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01329185
- **Lead sponsor:** University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06
- **Primary completion:** 2014-04
- **Final completion:** 2014-04
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2019-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01329185

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01329185, "Treating Kidney Donors With Valganciclovir to Reduce Viral Transmission to Recipients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01329185. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*